Irinotecan Eugia (Irinotecan Hydrochloride Trihydrate)

The drug is converted inside cells to the active metabolite SN‑38, which binds to the DNA‑topoisomerase I complex. This prevents the resealing of single‑strand DNA breaks during replication, leading to accumulation of DNA damage, inhibition of tumor cell proliferation, and eventual cell death.

The dosing regimen for Irinotecan Eugia is determined by the prescribing oncologist based on the patient’s clinical condition, body surface area, and treatment protocol. Specific dose amounts and schedules are individualized and should not be altered without medical guidance.

Irinotecan is classified as pregnancy category D, indicating evidence of risk to the fetus. It should be avoided during pregnancy unless the potential benefit justifies the risk. Breastfeeding is not recommended while receiving Irinotecan because the drug may be excreted in milk.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Irinotecan belongs to the topoisomerase I inhibitor class, offering a distinct mechanism from fluoropyrimidines (e.g., 5‑FU) and oxaliplatin. It is often combined with these agents to enhance efficacy. Compared with monotherapy, Irinotecan‑based regimens can provide greater tumor response but may increase the risk of neutropenia and diarrhea.

Irinotecan Eugia should be stored refrigerated at 2‑8 °C, protected from light, and never frozen. The product must be kept in its original packaging to maintain stability and should be handled using aseptic techniques during preparation for intravenous infusion.

The medication is given as an intravenous infusion, typically over 30 to 90 minutes depending on the treatment protocol. Administration is performed by qualified healthcare professionals in a clinical setting, with appropriate monitoring for infusion‑related reactions and toxicity.

The most serious adverse events include severe neutropenia (which can lead to infection), febrile neutropenia, life‑threatening diarrhea, and rare cases of severe colitis or hypersensitivity reactions. Prompt medical attention is required if any of these symptoms develop.

Patients with known hypersensitivity to Irinotecan or any of its excipients, those with severe bone‑marrow suppression, uncontrolled infections, or significant hepatic impairment should not receive the drug. Additionally, it is contraindicated in pregnant women unless the therapeutic benefit outweighs fetal risk.